Noncardiac comorbidities in heart failure with preserved ejection fraction – A Commonly ignored fact

Circulation Journal

Volumn 79, Issue 5, 2015, Pages 954-959

  Liu, Ming ^a   Fang, Fang ^a   Yu, Cheuk Man ^a  

^a CHINESE UNIVERSITY OF HONG KONG   (Hong Kong)

Author keywords

Diastolic dysfunction; Ejection fraction; Heart failure; Morbidity

Indexed keywords

ANEMIA; ARTICLE; CHRONIC OBSTRUCTIVE LUNG DISEASE; COMORBIDITY; HEART FAILURE WITH PRESERVED EJECTION FRACTION; HUMAN; HYPOALBUMINEMIA; HYPONATREMIA; MILD RENAL IMPAIRMENT; MODERATE RENAL IMPAIRMENT; MORTALITY; OBESITY; PEPTIC ULCER; SEVERE RENAL IMPAIRMENT; SLEEP DISORDERED BREATHING; THYROID DISEASE; HEART FAILURE; HEART STROKE VOLUME; RANDOMIZED CONTROLLED TRIAL (TOPIC);

COMORBIDITY; HEART FAILURE; HUMANS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; STROKE VOLUME;

EID: 84928492908     PISSN: 13469843     EISSN: 13474820     Source Type: Journal    
DOI: 10.1253/circj.CJ-15-0056     Document Type: Article

References (63)

1. Lam CS, Donal E, Kraigher-Krainer E, Vasan RS. Epidemiology and clinical course of heart failure with preserved ejection fraction. Eur J Heart Fail 2011; 13: 18 – 28.
2. Vasan RS, Levy D. Defining diastolic heart failure: A call for standardized diagnostic criteria. Circulation 2000; 101: 2118 – 2121.
3. Ather S, Chan W, Bozkurt B, Aguilar D, Ramasubbu K, Zachariah AA, et al. Impact of noncardiac comorbidities on morbidity and mortality in a predominantly male population with heart failure and preserved versus reduced ejection fraction. J Am Coll Cardiol 2012; 59: 998 – 1005.
4. Fonarow GC, Stough WG, Abraham WT, Albert NM, Gheorghiade M, Greenberg BH, et al. Characteristics, treatments, and outcomes of patients with preserved systolic function hospitalized for heart failure: A report from the OPTIMIZE-HF Registry. J Am Coll Cardiol 2007; 50: 768 – 777.
5. Yancy CW, Lopatin M, Stevenson LW, De MT, Fonarow GC. Clinical presentation, management, and in-hospital outcomes of patients admitted with acute decompensated heart failure with preserved systolic function: A report from the Acute Decompensated Heart Failure National Registry (ADHERE) database. J Am Coll Cardiol 2006; 47: 76 – 84.
6. Ahmed A, Rich MW, Fleg JL, Zile MR, Young JB, Kitzman DW, et al. Effects of digoxin on morbidity and mortality in diastolic heart failure: The ancillary digitalis investigation group trial. Circulation 2006; 114: 397 – 403.
7. Cleland JG, Tendera M, Adamus J, Freemantle N, Polonski L, Taylor J. The perindopril in elderly people with chronic heart failure (PEPCHF) study. Eur Heart J 2006; 27: 2338 – 2345.
8. Massie BM, Carson PE, McMurray JJ, Komajda M, McKelvie R, Zile MR, et al. Irbesartan in patients with heart failure and preserved ejection fraction. N Engl J Med 2008; 359: 2456 – 2467.
9. Yusuf S, Pfeffer MA, Swedberg K, Granger CB, Held P, McMurray JJ, et al. Effects of candesartan in patients with chronic heart failure and preserved left-ventricular ejection fraction: The CHARM-Preserved Trial. Lancet 2003; 362: 777 – 781.
10. Curtis JP, Sokol SI, Wang Y, Rathore SS, Ko DT, Jadbabaie F, et al. The association of left ventricular ejection fraction, mortality, and cause of death in stable outpatients with heart failure. J Am Coll Cardiol 2003; 42: 736 – 742.
11. Lee DS, Gona P, Albano I, Larson MG, Benjamin EJ, Levy D, et al. A systematic assessment of causes of death after heart failure onset in the community: Impact of age at death, time period, and left ventricular systolic dysfunction. Circ Heart Fail 2011; 4: 36 – 43.
12. Henkel DM, Redfield MM, Weston SA, Gerber Y, Roger VL. Death in heart failure: A community perspective. Circ Heart Fail 2008; 1: 91 – 97.
13. Smith GL, Lichtman JH, Bracken MB, Shlipak MG, Phillips CO, DiCapua P, et al. Renal impairment and outcomes in heart failure: Systematic review and meta-analysis. J Am Coll Cardiol 2006; 47: 1987 – 1996.
14. Rusinaru D, Buiciuc O, Houpe D, Tribouilloy C. Renal function and long-term survival after hospital discharge in heart failure with preserved ejection fraction. Int J Cardiol 2011; 147: 278 – 282.
15. Casado J, Montero M, Formiga F, Carrera M, Urrutia A, Arévalo JC, et al. Clinical characteristics and prognostic influence of renal dysfunction in heart failure patients with preserved ejection fraction. Eur J Intern Med 2013; 24: 677 – 683.
16. McAlister FA, Ezekowitz J, Tarantini L, Squire I, Komajda M, Bayes-Genis A, et al. Renal dysfunction in patients with heart failure with preserved versus reduced ejection fraction: Impact of the new Chronic Kidney Disease-Epidemiology Collaboration Group formula. Circ Heart Fail 2012; 5: 309 – 314.
17. Smith DH, Thorp ML, Gurwitz JH, McManus DD, Goldberg RJ, Allen LA, et al. Chronic kidney disease and outcomes in heart failure with preserved versus reduced ejection fraction: The Cardiovascular Research Network PRESERVE Study. Circ Cardiovasc Qual Outcomes 2013; 6: 333 – 342.
18. Rusinaru D, Buiciuc O, Leborgne L, Slama M, Massy Z, Tribouilloy C. Relation of serum sodium level to long-term outcome after a first hospitalization for heart failure with preserved ejection fraction. Am J Cardiol 2009; 103: 405 – 410.
19. Bavishi C, Ather S, Bambhroliya A, Jneid H, Virani SS, Bozkurt B, et al. Prognostic significance of hyponatremia among ambulatory patients with heart failure and preserved and reduced ejection fractions. Am J Cardiol 2014; 113: 1834 – 1838.
20. Gheorghiade M, Abraham WT, Albert NM, Gattis-Stough W, Greenberg BH, O’Connor CM, et al. Relationship between admission serum sodium concentration and clinical outcomes in patients hospitalized for heart failure: An analysis from the OPTIMIZE-HF registry. Eur Heart J 2007; 28: 980 – 988.
21. Lee DS, Austin PC, Rouleau JL, Liu PP, Naimark D, Tu JV. Predicting mortality among patients hospitalized for heart failure: Derivation and validation of a clinical model. JAMA 2003; 290: 2581 – 2587.
22. Lilly LS, Dzau VJ, Williams GH, Rydstedt L, Hollenberg NK. Hyponatremia in congestive heart failure: Implications for neurohormonal activation and responses to orthostasis. J Clin Endocrinol Metabol 1984; 59: 924 – 930.
23. Dzau VJ, Colucci WS, Hollenberg NK, Williams GH. Relation of the rennin-angiotensin-aldosterone system to clinical state in congestive heart failure. Circulation 1981; 63: 645 – 651.
24. Lee WH, Packer M. Prognostic importance of serum sodium concentration and its modification by converting-enzyme inhibition in patients with severe chronic heart failure. Circulation 1986; 73: 257 – 267.
25. Gheorghiade M, Rossi JS, Cotts W, Shin DD, Hellkamp AS, Pina IL, et al. Characterization and prognostic value of persistent hyponatremia in patients with severe heart failure in the ESCAPE trial. Arch Intern Med 2007; 167: 1998 – 2005.
26. Balmain S, Padmanabhan N, Ferrell WR, Morton JJ, McMurray JJ. Differences in arterial compliance, microvascular function and venous capacitance between patients with heart failure and either preserved or reduced left ventricular systolic function. Eur J Heart Fail 2007; 9: 865 – 871.
27. Cotter G, Metra M, Milo-Cotter O, Dittrich HC, Gheorghiade M. Fluid overload in acute heart failure-re-distribution and other mechanisms beyond fluid accumulation. Eur J Heart Fail 2008; 10: 165 – 169.
28. Uthamalingam S, Kandala J, Daley M, Patvardhan E, Capodilupo R, Moore SA, et al. Serum albumin and mortality in acutely decompensated heart failure. Am Heart J 2010; 160: 1149 – 1155.
29. Liu M, Chan CP, Yan BP, Zhang Q, Lam YY, Li RJ, et al. Albumin levels predict survival in patients with heart failure and preserved ejection fraction. Eur J Heart Fail 2012; 14: 39 – 44.
30. Don BR, Kaysen G. Serum albumin: Relationship to inflammation and nutrition. Semin Dial 2004; 17: 432 – 437.
31. Fuhrman MP, Charney P, Mueller CM. Hepatic proteins and nutrition assessment. J Am Diet Assoc 2004; 104: 1258 – 1264.
32. De Feo P, Lucidi P. Liver protein synthesis in physiology and in disease states. Curr Opin Clin Nutr Metab Care 2002; 5: 47 – 50.
33. Mitch WE. Malnutrition: A frequent misdiagnosis for hemodialysis patients. J Clin Invest 2002; 110: 437 – 439.
34. von Haehling S, van Veldhuisen DJ, Roughton M, Babalis D, de Boer RA, Coats AJ, et al. Anaemia among patients with heart failure and preserved or reduced ejection fraction: Results from the SENIORS study. Eur J Heart Fail 2011; 13: 656 – 663.
35. Maurer MS, Teruya S, Chakraborty B, Helmke S, Mancini D. Treating anemia in older adults with heart failure with a preserved ejection fraction with epoetin alfa: Single-blind randomized clinical trial of safety and efficacy. Circ Heart Fail 2013; 6: 254 – 263.
36. Anand IS, Kuskowski MA, Rector TS, Florea VG, Glazer RD, Hester A, et al. Anemia and change in hemoglobin over time related to mortality and morbidity in patients with chronic heart failure: Results from Val-HeFT. Circulation 2005; 112: 1121 – 1127.
37. Silverberg DS, Wexler D, Iaina A. The role of anemia in the progression of congestive heart failre: Is there a place for erythropoietin and intravenous iron? J Nephrol 2004; 17: 749 – 761.
38. Sandek A, Doehner W, Anker SD, von Haehling S. Nutrition in heart failure: An update. Curr Opin Clin Nutr Metab Care 2009; 12: 384 – 391.
39. Rozentryt P, von Haehling S, Lainscak M, Nowak JU, Kalantar-Zadeh K, Polonski L, et al. The effects of a high-caloric protein-rich oral nutritional supplement in patients with chronic heart failure and cachexia on quality of life, body composition, and inflammation markers: A randomized, double-blind pilot study. J Cachexia Sarcopenia Muscle 2010; 1: 35 – 42.
40. Kapoor JR, Heidenreich PA. Obesity and survival in patients with heart failure and preserved systolic function: A U-shaped relationship. Am Heart J 2010; 159: 75 – 80.
41. Haass M, Kitzman DW, Anand IS, Miller A, Zile MR, Massie BM, et al. Body mass index and adverse cardiovascular outcomes in heart failure patients with preserved ejection fraction: Results from the Irbesartan in Heart Failure with Preserved Ejection Fraction (I-PRESERVE) trial. Circ Heart Fail 2011; 4: 324 – 331.
42. Padwal R, McAlister FA, McMurray JJ, Cowie MR, Rich M, Pocock S, et al. The obesity paradox in heart failure patients with preserved versus reduced ejection fraction: A meta-analysis of individual patient data. Int J Obes (Lond) 2014; 38: 1110 – 1114.
43. Powell BD, Redfield MM, Bybee KA, Freeman WK, Rihal CS. Association of obesity with left ventricular remodeling and diastolic dysfunction in patients without coronary artery disease. Am J Cardiol 2006; 98: 116 – 120.
44. Mohamed-Ali V, Goodrick S, Bulmer K, Holly JM, Yudkin JS, Coppack SW. Production of soluble tumor necrosis factor receptors by human subcutaneous adipose tissue in vivo. Am J Physiol 1999; 277: E971 – E975.
45. Feldman AM, Combes A, Wagner D, Kadakomi T, Kubota T, Li YY, et al. The role of tumor necrosis factor in the pathophysiology of heart failure. J Am Coll Cardiol 2000; 35: 537 – 544.
46. Deswal A, Petersen NJ, Feldman AM, Young JB, White BG, Mann DL. Cytokines and cytokine receptors in advanced heart failure: An analysis of the cytokine database from the Vesnarinone trial (VEST). Circulation 2001; 103: 2055 – 2059.
47. Aquilani R, Opasich C, Verri M, Boschi F, Febo O, Pasini E, et al. Is nutritional intake adequate in chronic heart failure patients? J Am Coll Cardiol 2003; 42: 1218 – 1223.
48. Kinugasa Y, Kato M, Sugihara S, Hirai M, Yamada K, Yanagihara K, et al. Geriatric nutritional risk index predicts functional dependency and mortality in patients with heart failure with preserved ejection fraction. Circ J 2013; 77: 705 – 711.
49. Herrscher TE, Akre H, Overland B, Sandvik L, Westheim AS. High prevalence of sleep apnea in heart failure outpatients: Even in patients with preserved systolic function. J Card Fail 2011; 17: 420 – 425.
50. Bitter T, Faber L, Hering D, Langer C, Horstkotte D, Oldenburg O. Sleep-disordered breathing in heart failure with normal left ventricular ejection fraction. Eur J Heart Fail 2009; 11: 602 – 608.
51. Kwon BJ, Kim DB, Jang SW, Yoo KD, Moon KW, Shim BJ, et al. Prognosis of heart failure patients with reduced and preserved ejection fraction and coexistent chronic obstructive pulmonary disease. Eur J Heart Fail 2010; 12: 1339 – 1344.
52. Rusinaru D, Saaidi I, Godard S, Mahjoub H, Battle C, Tribouilloy C. Impact of chronic obstructive pulmonary disease on long-term outcome of patients hospitalized for heart failure. Am J Cardiol 2008; 101: 353 – 358.
53. Andrea R, López-Giraldo A, Falces C, Sobradillo P, Sanchis L, Gistau C, et al. Lung function abnormalities are highly frequent in patients with heart failure and preserved ejection fraction. Heart Lung Circ 2014; 23: 273 – 279.
54. Lam CS, Lyass A, Kraigher-Krainer E, Massaro JM, Lee DS, Ho JE, et al. Cardiac dysfunction and noncardiac dysfunction as precursors of heart failure with reduced and preserved ejection fraction in the community. Circulation 2011; 124: 24 – 30.
55. Masaki M, Komamura K, Goda A, Hirotani S, Otsuka M, Nakabo A, et al. Elevated arterial stiffness and diastolic dysfunction in subclinical hypothyroidism. Circ J 2014; 78: 1494 – 1500.
56. Selvaraj S, Klein I, Danzi S, Akhter N, Bonow RO, Shah SJ. Association of serum triiodothyronine with B-type natriuretic peptide and severe left ventricular diastolic dysfunction in heart failure with preserved ejection fraction. Am J Cardiol 2012; 110: 234 – 239.
57. Klein I, Danzi S. Thyroid disease and the heart. Circulation 2007; 116: 1725 – 1735.
58. Ascheim DD, Hryniewicz K. Thyroid hormone metabolism in patients with congestive heart failure: The low triiodothyronine state. Thyroid 2002; 12: 511 – 515.
59. Wassen FW, Schiel AE, Kuiper GG, Kaptein E, Bakker O, Visser TJ, et al. Induction of thyroid hormone-degrading deiodinase in cardiac hypertrophy and failure. Endocrinology 2002; 143: 2812 – 2815.
60. Rouf R, Greytak S, Wooten EC, Wu J, Boltax J, Picard M, et al. Increased FOG-2 in failing myocardium disrupts thyroid hormonedependent SERCA2 gene transcription. Circ Res 2008; 103: 493 – 501.
61. Kinugasa Y, Yamamoto K. Subclinical hypothyroidism as a new therapeutic target for patients with heart failure with preserved ejection fraction. Circ J 2014; 78: 1333 – 1334.
62. Liang KP, Myasoedova E, Crowson CS, Davis JM, Roger VL, Karon BL, et al. Increased prevalence of diastolic dysfunction in rheumatoid arthritis. Ann Rheum Dis 2010; 69: 1665 – 1670.
63. Senni M, Paulus WJ, Gavazzi A, Fraser AG, Diez J, Solomon SD, et al. New strategies for heart failure with preserved ejection fraction: The importance of targeted therapies for heart failure phenotypes. Eur Heart J 2014; 35: 2797 – 2815.